Trial Profile

A Phase 1, Multi-center, Open Label First-in-Human Study With ABBV-CLS-579 Alone and in Combination in Subjects With Locally Advanced or Metastatic Tumors

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 30 Sep 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ABBV-CLS-579 (Primary) ; Programmed cell death 1 receptor antagonists (Primary) ; Pembrolizumab; Vascular endothelial growth factor receptor antagonists
Indications Head and neck cancer; Non-small cell lung cancer; Renal cell carcinoma; Solid tumours; Squamous cell cancer
Focus Adverse reactions; First in man; Pharmacokinetics; Therapeutic Use
Sponsors AbbVie; Calico

Most Recent Events

24 Sep 2024 Planned number of patients changed from 263 to 101.
24 Sep 2024 Planned End Date changed from 30 Apr 2026 to 29 May 2026.
24 Sep 2024 Planned primary completion date changed from 29 Aug 2025 to 29 May 2026.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com